Enanta Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Enanta Pharmaceuticals has a total shareholder equity of $191.9M and total debt of $189.5M, which brings its debt-to-equity ratio to 98.8%. Its total assets and total liabilities are $428.5M and $236.6M respectively.
Key information
98.8%
Debt to equity ratio
US$189.55m
Debt
| Interest coverage ratio | n/a |
| Cash | US$337.15m |
| Equity | US$191.88m |
| Total liabilities | US$236.62m |
| Total assets | US$428.50m |
Recent financial health updates
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Recent updates
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Feb 04Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Nov 25Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts
Feb 11Financial Position Analysis
Short Term Liabilities: ENTA's short term assets ($390.3M) exceed its short term liabilities ($62.4M).
Long Term Liabilities: ENTA's short term assets ($390.3M) exceed its long term liabilities ($174.2M).
Debt to Equity History and Analysis
Debt Level: ENTA has more cash than its total debt.
Reducing Debt: ENTA's debt to equity ratio has increased from 0.4% to 98.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENTA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ENTA has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 54.5% each year.